Acinetobacter pneumonia: A review

MedGenMed Medscape General Medicine

Volumn 9, Issue 3, 2007, Pages

  Hartzell, Joshua D ^a,b   Kim, Andrew S ^b   Kortepeter, Mark G ^a,b   Moran, Kimberly A ^a,c  

^a Uniformed Services University of the Health Sciences   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BACTERIAL DNA; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; DNA TOPOISOMERASE; IMIPENEM; MEROPENEM; OUTER MEMBRANE PROTEIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BRONCHOSCOPY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DEVICE INFECTION; DISEASE COURSE; DNA DNA HYBRIDIZATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; EPIDEMIC; GENETIC CODE; GENOTYPE PHENOTYPE CORRELATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; LABORATORY TEST; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRAIN DIFFERENCE; TAXONOMY; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; BACTERIAL INFECTION; DRUG EFFECT;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL;

EID: 34447269413     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Jones A, Morgan D, Walsh A. Importation of multidrug-resistant Acinetobacter spp. infections with casualties from Iraq. Lancet Infect Dis. 2006;6:317-318.
2. Zapor MJ, Moran KA. Infectious diseases during wartime. Curr Opin Infect Dis. 2005;18:395-399.
3. Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11:1218-1224.
4. Centers for Disease Control. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004;53:1063-1066.
5. Jain R, Danziger L. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother. 2004;38:1449-1459.
6. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Repsir Crit Care Med. 1999;160:608-613.
7. Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;32(suppl 2):S104-S113.
8. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Coparison of ampicillin-sulbactam and imipenum-cilastin for treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34:1425-1430.
9. Erbay H, Yalcin AN, Serin S, et al. Nosocomial infections in intensive care unit in Turkish university hospital: a 2-year survey. Intensive Care Med. 2003;29:1482-1488.
10. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002;162:1515-1520.
11. Fournier P, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42:692-699. Epub 2006 Jan 26.
12. Patterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;43(suppl 2):S43-S48.
13. Poirel L, Menuteau O, Agoll N, Cattoen C, Nordmann P. Outbreak of extended-spectrum beta lactamase VEB-1-producing isolates of Acinetobacter baumannii in French hospital. J Clin Microbiol. 2003;41:3542-357.
14. Turton JF, Kaufmann ME, Warner M, et al. A prevalent, multiresistant clone of Acinetobacter baumannii in Southest England. J Hosp Infect. 2004;58:170-179.
15. Richards MJ, Edwards JR, Culver DH, Gayenes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infection Surveillance System. Crit Care Med. 1999;27:887-892.
16. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848-854.
17. Juni E. Interspecies transformation of Acinetobacter, genetic evidence for a ubiquitous genus. J Bacteriol. 1972;112:917-931.
18. Allen DM, Hartman BJ. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennetts Principles and Practice of Infectious Disease, 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005:2632-2626.
19. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-165.
20. La Scola B, Raoult D. Acinetobacter baumannii in human body louse. Emerg Infect Dis. 2004;10:1671-1673.
21. Gerner-Smidt P. Acinetobacter: epidemiological and taxonomic aspects. APMIS Suppl 1994;47:1-41.
22. Gervich DH, Grout CS. An outbreak of nosocomial Acinetobacter infections from humidifiers. Am J Infect Control. 1985;13:210-215.
23. Cefai C, Richards J, Gould FK, McPeake P. An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J Hops Infect. 1990;15:177-182.
24. Adams BG, Marrie TJ, Hand carriage of aerobic gram-negative rods by health care personnel. J Hyg. 1982;89:23-31.
25. Guenthner SH, Hendley JO, Wenzel RP. Gram-negative bacilli as non-transient flora on the hands of hospital personnel. J Clin Microbiol. 1987;25:488-490.
26. Sherertz RJ, Sullivan ML. An outbreak of infections with Acinetobacter calcoaceticus in burn patients: contamination of patients mattresses. J Infect Dis. 1985;151:252-258.
27. Weemik A, Severin WP, Tjemberg I, Dijkshoorn L. Pillows, an unexpected source of Acinetobacter. J Hosp Infect. 1995;29:189-199.
28. Neely AN, Maley MP, Warden GD. Computer keyboards as reservoirs for Acinetobacter baumannii in a burn hospital. Clin Infect Dis. 1999;29:1358-1360.
29. Catalano M, Quelle LS, Jeric PE, DiMartino A, Maimonet SM. Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect. 1999;42:27-35.
30. Al-Khoja MS, Darrell JH. The skin as the source of Acinetobacter and Moraxella species occurring in blood cultures. J Clin Pathol. 1979;32:497-499.
31. Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol. 2004;25:819-824.
32. Murray CK, Hospenthal DR. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis. 2005;18:502-506.
33. Griffith ME, Ceremuga JM, Ellis MW, et al. Acinetobacter Skin Colonization of US Army Soldiers. Infect Control Hosp Epidemiol. 2006;27:659-661.
34. Glew RH, Moellering RC Jr, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): Clinical and laboratory studies. Medicine. 1977;56:79-797.
35. Ayats J, Corbella X, Ardanuy C. Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect. 1997;37:287-295.
36. Peacock JE Jr. Sorrell L, Sottile FD, Price LE, Rutala WA. Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var anitratus: epidemiologic characteristics and clinical significance. Infect Control Hosp Epidemiol. 1988;9:302-308.
37. Griffith ME, Ellis MW, Murray CK. Acinetobacter nares colonization of healthy US soldiers. Infect Control Hosp Epidemiol. 2006;27:787-788.
38. Husni RN, Goldstein LS, Arroliga AC, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest. 1999;115:1378-1382.
39. Baraibar J, Correa H, Mariscal D, et al. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest. 1997;112:1050-1054.
40. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31:649-655.
41. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002; 122:262-268.
42. Jolly-Guillou M. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868-873.
43. Obana Y. Pathogenic significance of Acinetobacter calcoaceticus: analysis of experimental infection in mice. Microbiol Immunol. 1986;30:645-647.
44. Fournier PE, Vallenet D. Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genetics. 2006; 2:e7. Epub 2006 Jan 13.
45. Bonomo R, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43 Suppl 2:S49-S56.
46. Hujer K, Hujer A, Hulten E. Multi-drug resistant Acinetobacter spp. isolates from military and civilian patients treated at Walter Reed Army Medical Center: analysis of antibiotic resistance genes. Antimicrob Agents Chemother. 2006;50:4114-4123.
47. Walsh TR, Toleman MA, Poirel L, et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306-325.
48. Yum JH, Yi K, Lee H, et al. Molecular characterization of metallo-beta-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bia(VIM-2) gene cassettes. J Antimicrob-Chemother. 2002;49:837-840.
49. Lee K, Ha G, Shin B, et al. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis. 2004;50:51-58.
50. Da Silva G, Correria M, Vital C, et al. Molecular characterization of bla(IMP-5), a new integron-borne metallo-â-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol Lett. 2002;215:33-39.
51. Lesho E, Wortmann G, Moran K, et al. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis. 2005;41:758-759.
52. Beno P, Krcmery V, Demitrovocova A. Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect. 2006; 12:497-498.
53. Gilad J, Eskira S, Riesenberg K, et al. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. Program and abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC;
54. Hawley JS, Murray CK, Griffith ME, et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother. 2007;51:376-378.
55. Leung W, Chung-Ming C, Kay-Yang T, et al. Fulminant community-acquired Acinetobacter pneumonia as a distinct clinical syndrome. Chest. 2006;129:102-109.
56. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the northern territory of Australia. Clin Infect Dis. 1992;14:83-91.
57. Chen MZ, Hsueh PR, Lee LN, et al. Severe Community-acquired pneumonia due to Acinetobacter baumannii. Chest. 2001;120:1072-1077.
58. Achar KN, Johny M, Achar MN, et al. Community-acquired Acinetobacter pneumonia with survival. Post Grad Med J. 1993;69:934-937.
59. Bick JA, Semel JD. Fulminant Community-acquired Acinetobacter pneumonia in a healthy woman. Clin Infect Dis. 1993;17:820-821.
60. Bilgic H, Akin ES, Tasan Y, et al. A case of Acinetobacter calcaoceticus pneumonia. Thorax. 1995;50:315-316.
61. Yang CH, Chen KJ, Wang CK. Community-acquired Acinetobacter pneumonia: a case report. J Infect. 1997;35:316-318.
62. Goodhart GL, Abrutyn E, Watson R, et al. Community-acquired Acinetobacter calcaoceticus var anitratus pneumonia. JAMA. 1977;238:1516-1518.
63. Rudin ML, Michael JR, Huxley EJ. Community-acquired Acinetobacter pneumonia. Am J Med. 1979;67:39-43.
64. Vathesatogkit P, Charoenphan P, Saenghirunvattana S, et al. Community-acquired Acinetobacter pneumonia in Thailand. Report of 5 cases. J Med Assoc Thai. 1987;70:96-101.
65. Gottlieb T, Barnes DJ. Community-acquired Acinetobacter pneumonia. Aust N Z J Med. 1989;19:259-260.
66. Krisanapan S, Naphathorn P, Kaewprom P. Community acquired Acinetobacter pneumonia: report of two cases. Southeast Asian J Trop Med Public Health. 1989;20:497-498.
67. Michalopoulos A, Kasiakou S, Mastora. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care. 2005;9:R53-R59.
68. American Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
69. Bergogne-Berezin EB, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microblol Rev. 1996;9:148-65.
70. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumanii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-1118.
71. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006;4:138-146.
72. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005; 62:39-47.
73. Falagas ME, Kasiakou SK, Kofteridis DP, et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006;25:596-599.
74. Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005;49:3136-146.
75. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect. 2006; 53:274-278.
76. Falagas ME, Rafailidis PI, Jasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug- resistant Gram-negative bacterial infections. Clin Microbiol Infect. 2006;12:1227-1230.
77. Pino G, Contero G, Colongo PG. Clinical observations on the activity of aerosol colimycin and of endobronchial instillations of colimycin in patients with pulmonary suppurations. Minerva Med. 1963;54:2117-2122.
78. Marschke G, Sarauw A. Polymyxin inhalation therapeutic hazard. Ann Intern Med. 1971;74:144-145.
79. Li J, Nation R, Turnidge J, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6:589-601.
80. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multi-resistant Gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333-1341.
81. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis. 2006;48:S89-S94.
82. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multi-drug resistant Acinetobacter baumanii and Pseudomonas Aeruginosa. Clin Infect Dis. 2005;41:754-757.
83. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas Aeruginosa with aerosolized colistin. Am J Respir Crit Care Med. 2000;162:328-330.
84. Berlana D, Llop J, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health-Syst Pharm. 2005;62:39-47.
85. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
86. Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect. 2007;8:73-81.
87. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26:1187-1198.
88. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in Adult Patients. J Clin Pharmacol. 2006;46:1171-1178.
89. Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2006;58:697-700.
90. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis. 2005;37:195-199.
91. Sader H, Jones R. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents. 2005;25:380-384.
92. Marques MB, Brookings ES, Moser SA, et al. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother. 1997;41:881-885.
93. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004;54:1085-1091.
94. Falagas M, Kopterides P, Siempos I. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis. 2006;43:389; author reply 389-390.
95. Falagas M, Bliziotis I, Siempos I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10:R48.
96. Albrecht M, Griffith M, Murray C, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. 2006;203:546-550.
97. Sunenshine R. Wright M. Maragakis L. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97-103.
98. Jawad A, Seifert H, Snelling AM, et al. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol. 1998;36:1938-1941.
99. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol. 1997;35:1394-1397.
100. Aygun G, Demirkirian O, Utku T, et al. Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect. 2002;52:259-262.
101. Wagonvoort JHT, DeBrauwer EIGB, Toenbreker HMJ, van der Linden CJ. Epidemic Acinetobacter baumannii stain with MRSA-like behavior carried by healthcare staff. Eur J Clin Microbiol Infect Dis. 2002;21:326-327.
102. Harris A, McGregor J, Furuno J. What infection control interventions should be undertaken to control multi-drug resistant gram-negative bacteria? Clin Infect Dis. 2006;43:S57-S61.